MiMedx Group, Inc. (NASDAQ:MDXG) Given Average Recommendation of “Buy” by Analysts

Shares of MiMedx Group, Inc. (NASDAQ:MDXG) have received a consensus rating of “Buy” from the four ratings firms that are covering the company, Marketbeat reports. Four research analysts have rated the stock with a buy recommendation. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $12.25.

Several equities research analysts recently issued reports on the company. Mizuho lifted their price objective on MiMedx Group from $13.00 to $14.00 and gave the company a “buy” rating in a research note on Friday, March 1st. Lake Street Capital started coverage on MiMedx Group in a research note on Thursday, March 7th. They set a “buy” rating and a $12.00 price objective for the company.

Insider Buying and Selling at MiMedx Group

In other MiMedx Group news, CAO William Frank Iv Hulse sold 20,381 shares of the firm’s stock in a transaction dated Wednesday, March 13th. The stock was sold at an average price of $7.95, for a total transaction of $162,028.95. Following the sale, the chief accounting officer now owns 479,959 shares in the company, valued at $3,815,674.05. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, COO Ricci S. Whitlow sold 15,271 shares of MiMedx Group stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $8.01, for a total value of $122,320.71. Following the transaction, the chief operating officer now owns 401,050 shares in the company, valued at $3,212,410.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CAO William Frank Iv Hulse sold 20,381 shares of MiMedx Group stock in a transaction dated Wednesday, March 13th. The stock was sold at an average price of $7.95, for a total value of $162,028.95. Following the completion of the transaction, the chief accounting officer now owns 479,959 shares in the company, valued at approximately $3,815,674.05. The disclosure for this sale can be found here. Insiders have sold 51,145 shares of company stock worth $409,378 over the last 90 days. Corporate insiders own 19.90% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Optimist Retirement Group LLC purchased a new position in shares of MiMedx Group in the fourth quarter worth about $177,000. Cannell Capital LLC increased its holdings in shares of MiMedx Group by 9.1% in the fourth quarter. Cannell Capital LLC now owns 2,480,969 shares of the company’s stock worth $21,758,000 after buying an additional 207,207 shares during the period. Campbell & CO Investment Adviser LLC increased its holdings in shares of MiMedx Group by 26.9% in the fourth quarter. Campbell & CO Investment Adviser LLC now owns 261,604 shares of the company’s stock worth $2,294,000 after buying an additional 55,435 shares during the period. Hillsdale Investment Management Inc. increased its holdings in MiMedx Group by 69.2% during the 4th quarter. Hillsdale Investment Management Inc. now owns 447,900 shares of the company’s stock valued at $3,928,000 after purchasing an additional 183,141 shares during the period. Finally, Jump Financial LLC increased its holdings in MiMedx Group by 8.7% during the 4th quarter. Jump Financial LLC now owns 97,260 shares of the company’s stock valued at $853,000 after purchasing an additional 7,753 shares during the period. Hedge funds and other institutional investors own 79.15% of the company’s stock.

MiMedx Group Price Performance

NASDAQ:MDXG opened at $6.16 on Friday. The firm has a market capitalization of $909.09 million, a price-to-earnings ratio of 19.25 and a beta of 1.32. MiMedx Group has a 52-week low of $3.79 and a 52-week high of $9.27. The stock has a fifty day moving average of $7.39 and a 200 day moving average of $7.56. The company has a debt-to-equity ratio of 0.34, a quick ratio of 3.11 and a current ratio of 3.57.

MiMedx Group (NASDAQ:MDXG) last posted its quarterly earnings data on Wednesday, February 28th. The company reported $0.04 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.08 by ($0.04). The business had revenue of $86.83 million for the quarter, compared to the consensus estimate of $85.58 million. MiMedx Group had a net margin of 14.49% and a return on equity of 41.12%. On average, research analysts expect that MiMedx Group will post 0.33 EPS for the current fiscal year.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.